 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
16 News |  |
- ||| liafensine (DB104) / Denovo
Biomarker, Trial completion, Trial completion date, Trial primary completion date: ENLIGHTEN: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Apr 4, 2024
P2, N=197, Completed, Sponsor: Denovo Biopharma LLC
Recruiting --> Completed | Trial completion date: Jul 2024 --> Mar 2024 | Trial primary completion date: Jun 2024 --> Feb 2024
- | liafensine (DB104) / Denovo
Journal: Exploring and Engineering Novel Strong Promoters for High-Level Protein Expression in Bacillus subtilis DB104 through Transcriptome Analysis. (Pubmed Central) - Dec 23, 2023
Our work demonstrates the construction of a highly efficient expression system for B. subtilis DB104 based on transcriptome data and promoter engineering. This system enables rapid, inducer-free protein expression within 24 h. It can be used as a valuable tool for various industrial applications.
- | liafensine (DB104) / Denovo
Journal: Time-Course Transcriptome Analysis of Bacillus subtilis DB104 during Growth. (Pubmed Central) - Aug 26, 2023
However, the expression timing of the spore coat gene was only affected by the relevant sigma factor. This study can help to understand gene expression and regulatory mechanisms in B. subtilis species by providing an overall view of transcriptional changes during the growth of B. subtilis DB104.
- | liafensine (DB104) / Denovo
Journal: New robust subtilisins from halotolerant and halophilic Bacillaceae. (Pubmed Central) - Jun 5, 2023
This study can help to understand gene expression and regulatory mechanisms in B. subtilis species by providing an overall view of transcriptional changes during the growth of B. subtilis DB104. The protease genes were cloned and expressed in Bacillus subtilis DB104...
- | liafensine (DB104) / Denovo
Journal: Biochemical characterization of a novel oxidatively stable, halotolerant and high-alkaline subtilisin from Alkalihalobacillus okhensis Kh10-101. (Pubmed Central) - Oct 5, 2022
The protease gene was cloned and expressed in Bacillus subtilis DB104...The protease is highly oxidatively stable to hydrogen peroxide and retained 58 % of residual activity when incubated at 10 °C with 5 % (v/v) H O for 1 h while stimulated at 1 % (v/v) H O . Furthermore, SPAO was very stable and active at NaCl concentrations up to 5.0 M. This study demonstrates the potential of SPAO for biotechnological applications in the future.
- ||| liafensine (DB104) / Denovo
Biomarker, Enrollment open: ENLIGHTEN: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Jul 14, 2022
P2, N=180, Recruiting, Sponsor: Denovo Biopharma LLC
Furthermore, SPAO was very stable and active at NaCl concentrations up to 5.0 M. This study demonstrates the potential of SPAO for biotechnological applications in the future. Not yet recruiting --> Recruiting
- || liafensine (DB104) / Denovo
Biomarker, Trial completion date, Trial initiation date, Trial primary completion date: ENLIGHTEN: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Apr 12, 2022
P2, N=180, Not yet recruiting, Sponsor: Denovo Biopharma LLC
Not yet recruiting --> Recruiting Trial completion date: Apr 2024 --> Jul 2024 | Initiation date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2024 --> Jun 2024
- |||| liafensine (DB104) / Denovo
Biomarker, New P2 trial: ENLIGHTEN: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression (clinicaltrials.gov) - Nov 8, 2021
P2, N=180, Not yet recruiting, Sponsor: Denovo Biopharma LLC
- | liafensine (DB104) / Denovo
Preclinical, Journal: Umbelliferone Decorated Water-soluble Zinc(II) Phthalocyanines - In Vitro Phototoxic Antimicrobial Anti-cancer Agents. (Pubmed Central) - Oct 29, 2021
aureus strain 3150/12 and B. subtilis strain DB104) and Gram-negative bacteria (E...They are even capable to inactivate Gram-negative bacteria, whereas the dark toxicity remains low. These unique water-soluble compounds can be regarded as all-in-one type photosensitizers with broad applications ranges in the future.
- | liafensine (DB104) / Denovo
Journal: Decolorization of Acid Green 25 by Surface Display of CotA laccase on Bacillus subtilis spores. (Pubmed Central) - Jan 16, 2020
The optimum temperature for the decolorization of Acid Green 25 by the DB104 (pSDJH-EA) spore was found to be 50°C. Upon treatment with known laccase inhibitors, including EDTA, SDS, and NaN, the decolorization rate of Acid Green 25 by the DB104 (pSDJH-EA) spore decreased by 23%, 80%, and 36%, respectively.
- | liafensine (DB104) / Denovo
Journal: Bacillus subtilis Spore Surface Display of Haloalkane Dehalogenase DhaA. (Pubmed Central) - Nov 14, 2019
To this end, we cloned recombinant Bacillus subtilis spores pHY300PLK-cotg-dhaa-6his/DB104(FH01) for the delivery of DhaA from Rhodococcus rhodochrous NCIMB 13064...The hydrolyzing activity of DhaA displayed on spores towards the HD analog 2-chloroethyl ethylsulfide was 1.74 ± 0.06 U/mL (P < 0.01), with a specific activity was 0.34 ± 0.04 U/mg (P < 0.01). This is the first demonstration that DhaA displayed on the surface of B. subtilis spores retains enzymatic activity, which suggests that it can be used effectively in real-world applications including bioremediation of contaminated environments.
- | liafensine (DB104) / Denovo
Trial termination: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Nov 3, 2013
P2, N=789, Terminated, Sponsor: Bristol-Myers Squibb
This is the first demonstration that DhaA displayed on the surface of B. subtilis spores retains enzymatic activity, which suggests that it can be used effectively in real-world applications including bioremediation of contaminated environments. Recruiting --> Terminated; Failure to meet primary endpoint
- ||| liafensine (DB104) / Denovo
Trial initiation date: Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Jun 19, 2013
P2, N=889, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Terminated; Failure to meet primary endpoint Initiation date: Jan 2011 --> Apr 2011
- ||| liafensine (DB104) / Denovo
Enrollment change: Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Jun 19, 2013
P2, N=889, Completed, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 2011 --> Apr 2011 N=406 --> 889
- |||| liafensine (DB104) / Denovo
Trial completion: Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Jun 19, 2013
P2, N=889, Completed, Sponsor: Bristol-Myers Squibb
N=406 --> 889 Active, not recruiting --> Completed
- ||| liafensine (DB104) / Denovo
Enrollment change: Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Jun 3, 2013
P2, N=976, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=500 --> 976
- |||| liafensine (DB104) / Denovo
Trial completion: Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Jun 3, 2013
P2, N=976, Completed, Sponsor: Bristol-Myers Squibb
N=500 --> 976 Recruiting --> Completed
- ||| liafensine (DB104) / Denovo
Trial completion: Japanese Phase 1 Multiple Ascending Dose (MAD) Study (clinicaltrials.gov) - Jan 31, 2013
P1, N=57, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Recruiting --> Completed
- ||| liafensine (DB104) / Denovo
Trial initiation date: Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Mar 29, 2012
P2, N=976, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Completed Initiation date: Jan 1965 --> Jul 2011
- liafensine (DB104) / Denovo
Trial initiation date: Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression (clinicaltrials.gov) - Feb 1, 2012
P2, N=789, Terminated, Sponsor: Bristol-Myers Squibb
Initiation date: Jan 1965 --> Jul 2011 Initiation date: Feb 1963 --> Aug 2011